Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease
Authors:
Open Access
- 22 December 2019
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (4) , e1006-e1014
Abstract
Context Scarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD). Objective To evaluate the clinical utility and predictive value of TSAb/TBAb. Design Prospective 2-year trial. Setting Academic tertiary referral center. Patients One hundred consecutive, untreated, hyperthyroid GD patients. Methods TSAb was reported as percentage of specimen-to-reference ratio (SRR) (cutoff SRR < 140%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine thyrotropin (TSH, thyroid stimulating hormone) alone (cutoff > 40% inhibition). Main Outcome Measures Response versus nonresponse to a 24-week methimazole (MMI) treatment defined as biochemical euthyroidism versus persistent hyperthyroidism at week 24 and/or relapse at weeks 36, 48, and 96. Results Forty-four patients responded to MMI, of whom 43% had Graves orbitopathy (GO), while 56 were nonresponders (66% with GO; P < 0.01). At baseline, undiluted serum TSAb but not thyroid binding inhibitory immunoglobulins (TBII) differentiated between thyroidal GD-only versus GD + GO (P < 0.001). Furthermore, at baseline, responders demonstrated marked differences in diluted TSAb titers compared with nonresponders (P < 0.001). During treatment, serum TSAb levels decreased markedly in responders (P < 0.001) but increased in nonresponders (P < 0.01). In contrast, TBII strongly decreased in nonresponders (P = 0.002). All nonresponders and/or those who relapsed during 72-week follow-up period were TSAb-positive at week 24. A shift from TSAb to TBAb was noted in 8 patients during treatment and/or follow-up and led to remission. Conclusions Serum TSAb levels mirror severity of GD. Their increase during MMI treatment is a marker for ongoing disease activity. TSAb dilution analysis had additional predictive value.Keywords
This publication has 54 references indexed in Scilit:
- Analytical Performance and Clinical Utility of a Bioassay for Thyroid-Stimulating ImmunoglobulinsAmerican Journal of Clinical Pathology, 2013
- The American Thyroid Association/American Association of Clinical Endocrinologists Guidelines for Hyperthyroidism and Other Causes of Thyrotoxicosis: A European PerspectiveThyroid®, 2011
- Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical EndocrinologistsThyroid®, 2011
- Diagnostic Value of a Chimeric TSH Receptor (Mc4)-Based Bioassay for Graves' DiseaseThe Korean Journal of Internal Medicine, 2011
- Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulinsClinical and Experimental Immunology, 2010
- A Novel Bioreporter Assay for Thyrotropin Receptor Antibodies Using a Chimeric Thyrotropin Receptor (Mc4) Is More Useful in Differentiation of Graves' Disease from Painless Thyroiditis Than Conventional Thyrotropin-Stimulating Antibody Assay Using Porcine Thyroid CellsThyroid®, 2010
- Antithyroid drug regimen for treating Graves' hyperthyroidismCochrane Database of Systematic Reviews, 2010
- Relevance of TSH Receptor Stimulating and Blocking Autoantibody Measurement for the Prediction of Relapse in Graves’ DiseaseHormone and Metabolic Research, 2005
- Characterization of Thyroid-Stimulating Blocking Antibodies That Appeared During Transient Hypothyroidism After Radioactive Iodine TherapyThyroid®, 2000
- Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH‐binding inhibitor immunoglobulinClinical Endocrinology, 1994